Skip to main content

Mainolfi Nello's Form 4 filing

Kymera Therapeutics, Inc. (KYMR) · filed Feb 25, 2026

Accession no.
0001193125-26-072155
Filed
Feb 25, 2026
Trade date
Feb 25, 2026
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.71M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mainolfi NelloCIK 0001821189Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 25, 2026Common StockMOption exerciseAcquired+30,000$2.08+$62,400696,195Direct
Feb 25, 2026Common StockSSaleDisposed−19,764$89.78−$1,774,411.92676,431Direct
Feb 25, 2026Common StockSSaleDisposed−5,434$90.39−$491,179.26670,997Direct
Feb 25, 2026Common StockSSaleDisposed−3,293$91.76−$302,165.68667,704Direct
Feb 25, 2026Common StockSSaleDisposed−1,501$92.81−$139,307.81666,203Direct
Feb 25, 2026Common StockSSaleDisposed−8$93.49−$747.92666,195Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 25, 2026Common StockMOption exerciseDisposed−30,000$0.00$0245,559Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)